Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 保健營養系(所) > 期刊論文 > Item 310902800/34707

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34707

標題:	Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
作者:	Sun, Hsin-Yun Cheng, Chien-Yu Lin, Chi-Ying Yang, Chia-Jui Lee, Nan-Yao Liou, Bo-Huang Tang, Hung-Jen Liu, Yuang-Meng Lee, Chun-Yuan Chen, Tun-Chieh Huang, Yi-Chia Lee, Yuan-Ti Tsai, Ming-Jui Lu, Po-Liang Tsai, Hung-Chin Wang, Ning-Chi Hung, Tung-Che Cheng, Shu-Hsing Hung, Chien-Ching
貢獻者:	National Taiwan University National Taiwan University Hospital National Yang Ming Chiao Tung University National Taiwan University Hospital Far Eastern Memorial Hospital National Cheng Kung University National Cheng Kung University Hospital Mackay Memorial Hospital Chi Mei Hospital Department of Health and Nutrition, Chia Nan University of Pharmacy & Science Changhua Christian Hospital Kaohsiung Medical University Kaohsiung Medical University Hospital Kaohsiung Medical University National Taiwan University National Taiwan University Hospital Chung Shan Medical University Chung Shan Medical University Hospital Chung Shan Medical University Kaohsiung Medical University Kaohsiung Medical University Hospital Kaohsiung Veterans General Hospital National Defense Medical Center Tri-Service General Hospital National Taiwan University China Medical University Taiwan China Medical University Hospital - Taiwan
關鍵字:	taiwan consensus statement therapy management
日期:	2022
上傳時間:	2023-12-11 14:06:18 (UTC+8)
出版者:	BAISHIDENG PUBLISHING GROUP INC
摘要:	BACKGROUND Hepatitis C virus (HCV) genotype 6 (HCV-6) infection is prevalent predominantly in Southeast Asia, and the data on the virologic response of HCV-6 to direct-acting antivirals (DAAs) are sparse in people living with human immunodeficiency virus (HIV) (PLWH). AIM To assess the virologic response of HCV-6 to DAAs in PLWH. METHODS From September 2016 to July 2019, PLWH coinfected with HCV-6 initiating DAAs were included. Laboratory investigations were performed at baseline, the end of treatment, and 12 wk off-therapy. RESULTS Of the 349 PLWH included (mean age 48.9 years, 82.5% men), 80.5% comprised people who inject drugs, 18.1% men who have sex with men, and 1.4% heterosexuals. Coexistent hepatitis B virus infection was present in 12.3% of the included PLWH, liver cirrhosis 10.9%, hepatocellular carcinoma 0.9%, and previous HCV treatment experience 10.9%. The mean baseline plasma HCV RNA was 6.2 log 10 IU/mL. Treatment with glecaprevir/pibrentasvir was initiated in 51.9%, sofosbuvir/ledipasvir 41.5%, sofosbuvir/velpatasvir 6.3%, and sofosbuvir/daclatasvir 0.3%. At DAA initiation, antiretroviral therapy containing tenofovir alafenamide was given in 26.4%, tenofovir disoproxil fumarate 34.4%, non-tenofovir alafenamide/tenofovir disoproxil fumarate 39.3%, non- nucleoside reverse-transcriptase inhibitors 30.4%, protease inhibitors 4.0%, and integrase strand transfer inhibitors 66.8%; 94.8% of the included patients had CD4 counts = 200 cells/mm3 and 96.0% had plasma HIV RNA < 50 copies/mL. Overall, 96.8% achieved undetectable plasma HCV RNA (< 30 IU/mL) at end of treatment; and 92.3% achieved sustained virologic response 12 wk off-therapy in the intention-to-treat analysis (93.5% in patients receiving sofosbuvir-based DAAs and 91.2% in those receiving glecaprevir/pibrentasvir). CONCLUSION Similar to the observation made in HIV-negative patients, sustained virologic response 12 wk offtherapy with DAAs is high in PLWH coinfected with HCV-6.
關聯:	WORLD JOURNAL OF GASTROENTEROLOGY, v.28, n.11, pp.1088-1186
显示于类别:	[保健營養系(所) ] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	246	检视/开启
WJG-28-1172.pdf		1029Kb	Adobe PDF	47	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....